ArticleScientific reports2021
Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Topological Stability and Transcritical Bifurcations in a Target-Cell-Limited Model of HBV-HDV Viral Interference.Viruses · 2026Article
- Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B.Nature communications · 2026Article
- Clinical trial simulation of antiviral drugs.Journal of virology · 2026Review
- Investigation of a Two-Patch Within-Host Model of Hepatitis B Viral Infection.Bulletin of mathematical biology · 2025Article
- Genomic medicine in hepatology: mechanisms and liver treatment strategies.Molecular medicine (Cambridge, Mass.) · 2025Review
- Modeling of hepatitis B virus infection spread in primary human hepatocytes.Journal of virology · 2025Article
- Bistability between acute and chronic states in a Model of Hepatitis B Virus Dynamics.Mathematical biosciences · 2025Article
- A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens.Frontiers in immunology · 2025Article
- Review
- Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.JHEP reports : innovation in hepatology · 2024Article
- Incorporating Intracellular Processes in Virus Dynamics Models.Microorganisms · 2024Review
- Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers.PLoS computational biology · 2024Article
- Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.JHEP reports : innovation in hepatology · 2024Article
- Review
- Review
- Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients.Mathematics (Basel, Switzerland) · 2022Article
- Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice.Journal of virology · 2021Article
- A Simple and Rapid Method for Quantitative Detection of Hepatitis B Virus Drug-resistant Mutations.Journal of clinical and translational hepatology · 2021Article
- Review
- Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir). To provide insights into HBV dynamics under ARC-520 treatment and its efficacy in blocking HBV DNA, HBsAg, and HBeAg production we developed a multi-compartmental pharmacokinetic-pharamacodynamic model and calibrated it with frequent measured HBV kinetic data. We showed that the time-dependent single dose ARC-520 efficacies in blocking HBsAg and HBeAg are more than 96% effective around day 1, and slowly wane to 50% in 1-4 months. The combined single dose ARC-520 and entecavir effect on HBV DNA was constant over time, with efficacy of more than 99.8%. The observed continuous HBV DNA decline is entecavir mediated, the strong but transient HBsAg and HBeAg decays are ARC-520 mediated. The modeling framework may help assess ongoing RNAi drug development for hepatitis B virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.